Innovent Bio (01801.HK) and Beijing Aosaikang Pharmaceutical (002755.SZ) recently signed a cooperation agreement. Both parties will achieve exclusive commercial cooperation on the third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) targeted drug 'Elutherinib tablets' (trade name: Ao Yixin).

Beijing Aosaikang Pharmaceutical will act as the licensee holder for the collaborative product, responsible for the commercial production and supply of the collaborative product, and will pay Innovent Bio sales promotion service fees according to the cooperation agreement. Innovent Bio will obtain the exclusive promotion and sales rights of the collaborative product in mainland China, and will pay Beijing Aosaikang Pharmaceutical down payment, registration milestone, and sales milestone fees according to the cooperation agreement.

The National Medical Products Administration is currently reviewing and approving two new drug market applications for Elutherinib tablets, for: Patients with locally advanced or metastatic non-small cell lung cancer in adults with EGFR exon 19 deletions, or exon 21 (L858R) substitution mutations, as first-line treatment. The other indication being for patients who have disease progression after treatment with EGFR tyrosine kinase inhibitors (TKIs) or after disease progression, and whose tumors have been tested and confirmed to be EGFR T790M mutation positive or have primary EGFR T790M mutation positive.

Yu Dechao, founder, director, chairman, and CEO of Innovent Bio, stated that the collaboration with Beijing Aosaikang on Ao Yixin is expected to provide a new targeted drug for a broad range of EGFR mutation lung cancer patients, while further enhancing Innovent Bio's leading position in the field of oncology treatment.